After Capricor Therapeutics’ October 7 webinar on new positive data for its Duchenne muscular dystrophy (DMD) treatment deramiocel, Oppenheimer reiterated its Outperform rating and $54.00 price target. The webinar covered HOPE-3 open-label extension data and updates ahead of the drug’s scheduled November 22, 2026 PDUFA date.
Oppenheimer said the reiterated target implies significant upside from Capricor’s trading price. Its analyst note highlighted the robustness of the data submitted to the FDA, including numerous alternative analyses supporting deramiocel’s efficacy on upper limb function in DMD patients.
The analyst action comes as Capricor awaits the FDA’s decision on its Biologics License Application for deramiocel.